FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response.	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an															
Name and Address of Reporting Person * Shenouda Maged			2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Middle) C/O RELMADA THERAPEUTICS, INC., 750 THIRD AVENUE, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 10/20/2017					•	Officer (give	title below)	Oth	er (specify below			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
NEW YO	ORK, NY 1	.0016									Form filed by l	More than One	Reporting Persor		
(Cir	ity)	(State)	(Zip)			Tabl	le I - 1	Non-Deriva	ative Securitie	s Acqui	red, Disposed	of, or Bene	ficially Owi	ied	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			on Date, if Code (Instr		(A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of S Owned Follow Γransaction(s)		ed OFC D or (I	Ownership o	Nature Indirect eneficial
								v V Ai	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership Instr. 4)
Reminder:	Report on a	separate line for each						Persons contain form dis	s who respor ed in this for splays a curr	m are r ently v	not required alid OMB co	to respon	d unless th		174 (9-02)
		_							sed of, or Beno vertible secur		Owned				
1. Title of Derivative Security (Instr. 3)	2.	(Month/Day/Year)	3A. Deemed Execution Date, if ear) any (Month/Day/Year)							itics					
Derivative Security	Conversion	Date	Execution Date, if any	Code)		(A)	_	ercisable and Date	7. Title of Und Securit			9. Number Derivative Securities Beneficially Owned Following Reported Transaction	Ownershi Form of Derivative Security: Direct (D or Indirect	(Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	Execution Date, if any	Transac Code)	Derivative Securities Acquired or Dispose of (D) (Instr. 3, 4 and 5)	(A) ed	6. Date Exe Expiration	ercisable and Date y/Year) Expiration	7. Title of Und Securit	erlying ies	Derivative Security	Derivative Securities Beneficially Owned Following Reported	Ownershi Form of Derivative Security: Direct (D or Indirect	of Indirect Beneficial Ownersh (Instr. 4)

Doministra Common Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Shenouda Maged C/O RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE, 9TH FLOOR NEW YORK, NY 10016	Х					

Signatures

/s/ Maged Shenouda	10/23/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.